Literature DB >> 18564764

Evaluation of the mood-stabilizing agent valproic acid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice.

David G Goodwin1, Jeannine Strobl, Sheila M Mitchell, Anne M Zajac, David S Lindsay.   

Abstract

Toxoplasma gondii is a common intracellular protozoan infection of humans worldwide. Severe disease can occur in immunocompromised individuals and the in the fetuses of nonimmune pregnant women. Chronic infection is associated with vision and hearing problems, and functional mental alterations, including schizophrenia. The mood-stabilizing agent valproic acid has been shown to inhibit the development of T. gondii in vitro at dosages that are normally achieved in the serum and cerebral spinal fluid of human patients and to have positive effects on the behavior of rats chronically infected with T. gondii. The present study was done to examine the in vivo activity of valproic acid against acute toxoplasmosis in mice. Two studies were done with valproic acid given in the drinking water at concentrations of 1.5 mg/ml (Experiment 1) or 3.0 mg/ml (Experiment 2). In a third experiment (Experiment 3), valproic acid was injected intraperitoneally (i.p.) at doses of 200 or 300 mg/kg every 12 hr. Valproic acid was not effective in preventing acute toxoplasmosis. All mice treated with valproic acid died or were killed and did not (P > 0.05) live significantly longer than the controls. Tachyzoites were demonstrated in the tissues of infected valproic-acid-treated mice. A fourth study was done to determine if valproic acid has activity against T. gondii tissue cysts in chronically infected mice. Mice were chronically infected with the ME-49 strain of T. gondii for 8 wk and then treated orally with valproic acid at approximately 6.6 mg/ml (800 mg/kg/day) in the drinking water for 10 wk (amount was varied due to increasing mouse weights). No significant differences (P > 0.05) were present in tissue cyst numbers in valproic-acid-treated T. gondii chronically infected mice and in mice chronically infected with T. gondii but not given valproic acid. Our results indicate that valproic acid, although effective in vitro against T. gondii tachyzoites, is not effective as a preventative in mice inoculated with T. gondii tachyzoites. Additionally, no activity against tissue cysts was observed in chronically T. gondii-infected valproic-acid-treated mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18564764     DOI: 10.1645/GE-1331.1

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  11 in total

Review 1.  The known and missing links between Toxoplasma gondii and schizophrenia.

Authors:  Hany M Elsheikha; Dietrich Büsselberg; Xing-Quan Zhu
Journal:  Metab Brain Dis       Date:  2016-04-04       Impact factor: 3.584

2.  Toxoplasma gondii infection in slaughtered domestic ruminants in Northwest Ethiopia: occurrence, bioassay and virulence assessment.

Authors:  Moges Maru; Debasu Damtie; Ambaye Kenubih; Abiy Maru; Biyansa Adugna; Shimelis Dagnachew; Zewdu Seyoum Tarekegn
Journal:  J Parasit Dis       Date:  2022-01-22

Review 3.  Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review.

Authors:  Mahbobeh Montazeri; Saeed Mehrzadi; Mehdi Sharif; Shahabeddin Sarvi; Shayesteh Shahdin; Ahmad Daryani
Journal:  Parasitol Res       Date:  2018-08-08       Impact factor: 2.289

4.  The Effect of Fluphenazine and Thioridazine on Toxoplasma gondii In Vivo.

Authors:  Mehrzad Saraei; Yosef Ghaderi; Tahereh Mosavi; Mojtaba Shahnazi; Marjan Nassiri-Asl; Hassan Jahanihashemi
Journal:  Iran J Parasitol       Date:  2016 Apr-Jun       Impact factor: 1.012

Review 5.  Is Toxoplasma gondii a Trigger of Bipolar Disorder?

Authors:  Claudia Del Grande; Luca Galli; Elisa Schiavi; Liliana Dell'Osso; Fabrizio Bruschi
Journal:  Pathogens       Date:  2017-01-10

6.  Valproic Acid Inhibits Chronic Toxoplasma Infection and Associated Brain Inflammation in Mice.

Authors:  Marjan Enshaeieh; Geita Saadatnia; Jalal Babaie; Majid Golkar; Samira Choopani; Mohammad Sayyah
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191

7.  Latent toxoplasmosis and human.

Authors:  A Dalimi; A Abdoli
Journal:  Iran J Parasitol       Date:  2012       Impact factor: 1.012

8.  Limited Effect of Chronic Valproic Acid Treatment in a Mouse Model of Machado-Joseph Disease.

Authors:  Sofia Esteves; Sara Duarte-Silva; Luana Naia; Andreia Neves-Carvalho; Andreia Teixeira-Castro; Ana Cristina Rego; Anabela Silva-Fernandes; Patrícia Maciel
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

9.  In vivo anti-Toxoplasma activity of aripiprazole.

Authors:  Mehrzad Saraei; Nafiseh Samadzadeh; Javad Khoeini; Mojtaba Shahnazi; Marjan Nassiri-Asl; Hasan Jahanihashemi
Journal:  Iran J Basic Med Sci       Date:  2015-09       Impact factor: 2.699

10.  Isolation and genotyping of viable Toxoplasma gondii from sheep and goats in Ethiopia destined for human consumption.

Authors:  Endrias Zewdu Gebremedhin; Mukarim Abdurahaman; Tesfaye Sisay Tessema; Getachew Tilahun; Eric Cox; Bruno Goddeeris; Pierre Dorny; Stephane De Craeye; Marie-Laure Dardé; Daniel Ajzenberg
Journal:  Parasit Vectors       Date:  2014-09-04       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.